8-K: Petros Pharmaceuticals Faces Nasdaq Delisting Due to Stockholder Equity, Bid Price, and Public Interest Concerns

Petros Pharmaceuticals, Inc. received notice from Nasdaq that its securities will be delisted due to non-compliance with listing rules and public interest concerns.

Summary

• Petros Pharmaceuticals received a letter from the Nasdaq Hearings Panel on May 20, 2025, indicating the Panel's decision to delist the company's securities.
• The delisting is due to the company's failure to maintain the minimum stockholders' equity, failure to meet the minimum bid price of $1.00 per share, low bid price, and public interest concerns related to a public offering that closed on February 19, 2025.
• Trading of the company's common stock will be suspended on Nasdaq at the open of trading on May 22, 2025.
• The company expects its common stock to trade on the OTC Markets under the symbol PTPI beginning on May 22, 2025.
• Petros Pharmaceuticals plans to request a review of the delisting determination by the Nasdaq Listing and Hearing Review Council.
• Requesting a review will delay the filing of Form 25 with the SEC but will not prevent the suspension of trading on Nasdaq.
• There is no guarantee that the Listing Council will approve the company's request for continued listing on Nasdaq.

Sentiment

Score: 2

Explanation: The sentiment is negative due to the delisting notice, indicating financial and compliance issues. The appeal provides a slight glimmer of hope, but the overall outlook is concerning.

Positives

• Petros Pharmaceuticals intends to appeal the delisting decision, which will temporarily delay the formal delisting process.

Negatives

• Petros Pharmaceuticals is being delisted from Nasdaq.
• The company failed to maintain the minimum stockholders' equity requirement.
• The company failed to meet the minimum bid price of $1.00 per share.
• Nasdaq has public interest concerns regarding the company's public offering of securities that closed on February 19, 2025.
• Trading of the company's common stock will be suspended on Nasdaq on May 22, 2025.

Risks

• There is no assurance that the Nasdaq Listing and Hearing Review Council will grant the company's request for continued listing on Nasdaq.
• Delisting from Nasdaq could negatively impact the company's stock price and investor confidence.

Future Outlook

The company expects its Common Stock will trade publicly on the OTC Markets under its existing symbol PTPI beginning on May 22, 2025 and will request an appeal of the delisting determination by the Listing Council.

Management Comments

• Fady Boctor, President and Chief Commercial Officer, signed the report on behalf of Petros Pharmaceuticals, Inc.

Industry Context

Delisting from a major exchange like Nasdaq can significantly impact a company's visibility and access to capital, often leading to increased volatility and decreased investor confidence. Companies facing delisting often explore options such as reverse stock splits, restructuring, or seeking alternative funding to regain compliance.

Comparison to Industry Standards

• Companies like CitiusTech and Titan Machinery, which have faced similar listing compliance issues, often implement strategies such as reverse stock splits or significant operational changes to regain compliance.
• Compared to industry peers, Petros Pharmaceuticals' failure to maintain minimum stockholders' equity and bid price suggests potential financial instability relative to companies that consistently meet these requirements.

Stakeholder Impact

• Shareholders may experience a decline in stock value due to the delisting.
• Employees may face uncertainty regarding the company's future.
• The company's ability to raise capital may be negatively impacted.

Next Steps

• Petros Pharmaceuticals will request a review of the delisting determination by the Nasdaq Listing and Hearing Review Council.
• The company will transition its stock trading to the OTC Markets under the symbol PTPI on May 22, 2025.
• The Nasdaq Listing and Hearing Review Council will review the delisting determination.

Key Dates

Keywords

delisting, Nasdaq, Petros Pharmaceuticals, stockholders' equity, minimum bid price, public offering, PTPI, OTC Markets